DGAP-News: Update: EDMOND DE ROTHSCHILD INVESTMENT PARTNERS SELLS ITS PARTICIPATION IN SAPIENS STEERING BRAIN STIMULATION, DEVELOPER OF DEEP BRAIN STIMULATION SOLUTIONS TO MEDTRONIC

DGAP-News: Edmond de Rothschild Investment Partners / Key word(s):
Investment
Update: EDMOND DE ROTHSCHILD INVESTMENT PARTNERS SELLS ITS
PARTICIPATION IN SAPIENS STEERING BRAIN STIMULATION, DEVELOPER OF DEEP
BRAIN STIMULATION SOLUTIONS TO MEDTRONIC

26.08.2014 / 13:09

---------------------------------------------------------------------

EDMOND DE ROTHSCHILD INVESTMENT PARTNERS SELLS ITS PARTICIPATION IN SAPIENS
STEERING BRAIN STIMULATION, DEVELOPER OF DEEP BRAIN STIMULATION SOLUTIONS
TO MEDTRONIC

This operation is the sixth trade sale of BioDiscovery 3, the fourteenth
from the BioDiscovery funds

Edmond De Rothschild Investment Partners (EdRIP) announced today that its
BioDiscovery 3 portfolio company, Sapiens Steering Brain Stimulation
(Sapiens SBS) a privately held developer of deep brain stimulation (DBS)
technologies, has been acquired by Medtronic, Inc. (NYSE: MDT) for
approximately $200 million in an all-cash transaction.

Sapiens SBS, located in Eindhoven, The Netherlands, is developing a DBS
system that features an advanced DBS lead with 40 individual stimulation
points. This advanced system is designed to allow more precise stimulation
of the intended target in the brain and may potentially result in reduced
procedure time and fewer stimulation-induced side effects.

Employees at the Eindhoven facility will continue to work toward bringing
this technology to market. In the future, the site will serve as a global
research and development center for Medtronic's Neuromodulation business,
complementing its existing R&D operations.

Medtronic and Sapiens SBS will work to finalize product development and
begin clinical research to integrate these technologies into an expanded
portfolio of DBS products within Medtronic's Neuromodulation business.

EdRIP co-led the series A round of Sapiens SBS as a spin-off from Philips
Healthcare in 2011 to back the founders Sjaak Deckers, Hubert Martens and
Michel Decre who believed that a much better resolution of the applied
current in deep brain stimulation (DBS), could significantly improve the
therapeutic window of DBS.

In a very short time frame, Sapiens confirmed its initial hypothesis in
acute human trials in Parkinson patients and became a clear leader in
developing significantly improved devices for DBS therapeutic applications.
In 2013, medtech veteran Jan Keltjens became the company's CEO and under
his leadership the product was further advanced and refined.

"Since 2011, Sapiens SBS employees have worked tirelessly to develop an
advanced deep brain stimulation system," said Jan Keltjens, chief executive
officer at Sapiens SBS. "We are excited to join Medtronic, and look forward
to collectively working to bring this and other novel technologies and
therapies to neuromodulation patients worldwide that could benefit from
them."

"In only about 3 years, Sapiens SBS has achieved a lot. Also, the way
founders, management, board and investors have worked together in this
company is, in my opinion, quite exceptional. Through this trade sale, in
addition to making good return for our Limited Partners, it is very
satisfying to see now the Sapiens' products integrated into the
neurostimulation franchise of the DBS market leader, as it gives this
technology the best chances of helping patients in the near future" says
Olivier Litzka, Partner at EdRIP.

Sapiens was the thirteenth investment of BioDiscovery 3, a specialized life
science investment fund managed by Edmond de Rothschild Investment
Partners. Raised in 2008, the Fund has invested from 2008 to 2012 in a
portfolio of 14 companies. So far six of these companies have been sold
through private transactions and two have been listed on public financial
markets.

About Edmond de Rothschild Investment Partners

Edmond de Rothschild Investment Partners is the private equity affiliate of
the Edmond de Rothschild Group, which is specialized in asset management
and private banking (EUR 133.6bn under management, nearly 2,800 employees
spread across 31 offices, branches and subsidiaries throughout the world).
Founded in 1953, the Group has been chaired since 1997 by Baron Benjamin de
Rothschild.

Paris-based Edmond de Rothschild Investment Partners is dedicated to
minority investments into privately-owned companies. It currently has more
than EUR1 billion under management which is being invested primarily as
life sciences venture capital and growth capital.

Within Edmond de Rothschild Investment Partners, its Life Sciences Team of
eight professionals brings together over 60 years of experience in the Life
Science industry and more than 100 years of private equity and venture
capital experience. The Team has raised EUR450 million through its
Biodiscovery franchise and is currently investing BioDiscovery 4. Since
inception, BioDiscovery Funds have invested in 49 companies, of which 13
have been sold and 12 listed on public financial markets. 19 are still
active in the portfolios.

BioDiscovery Funds, including BioDiscovery 4, are venture capital funds
dedicated to professional investors. These funds are not authorized by the
Autorité des Marchés Financiers and may adopt special investment rules.

For more information : www.edrip.fr

Contacts

Edmond de Rothschild Investment Partners

Olivier Litzka

o.litzka@edr.com

Tel:  +33 1 40 17 27 46



---------------------------------------------------------------------

26.08.2014 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


283955 26.08.2014